Department of Hepato-gastroenterology B, Hôpital Saint Eloi, Centre Hospitalier Universitaire de Montpellier, France.
Ann Hepatol. 2012 May-Jun;11(3):369-83.
To perform an updated meta-analysis comparing β-blockers (BB) with endoscopic variceal banding ligation (EVBL) in the primary prophylaxis of esophageal variceal bleeding.
Randomized controlled trials were identified through electronic databases, article reference lists and conference proceedings. Analysis was performed using both fixed-effect and random-effect models. Heterogeneity and publication bias were systematically taken into account. Main outcomes were variceal bleeding rates and all-cause mortality, calculated overall and at 6, 12, 18 and 24 months.
19 randomized controlled trials were analyzed including a total of 1,483 patients. Overall bleeding rates were significantly lower for the EVBL group: odds ratio (OR) 2.06, 95% confidence interval (CI) [1.55-2.73], p < 0.0001, without evidence of publication bias. Bleeding rates were also significantly lower at 18 months (OR 2.20, 95% CI [1.04-4.60], P = 0.04), but publication bias was detected. When only high quality trials were taken into account, results for bleeding rates were no longer significant. No significant difference was found for either bleeding-related mortality or for all-cause mortality overall or at 6, 12, 18 or 24 months. BB were associated with more frequent severe adverse events (OR 2.61, 95% CI 1.60-4.40, P < 0.0001) whereas fatal adverse events were more frequent with EVBL (OR 0.14, 95% CI 0.02-0.99, P = 0.05).
EVBL appears to be superior to BB in preventing the first variceal bleed, although this finding may be biased as it was not confirmed by high quality trials. No difference was found for mortality. Current evidence is insufficient to recommend EVBL over BB as first-line therapy.
对比较β受体阻滞剂(BB)与内镜下食管静脉曲张套扎术(EVBL)在预防食管静脉曲张出血的一级预防中的作用进行更新的荟萃分析。
通过电子数据库、文章参考文献列表和会议记录确定随机对照试验。使用固定效应和随机效应模型进行分析。系统地考虑了异质性和发表偏倚。主要结局为静脉曲张出血率和全因死亡率,总体和 6、12、18 和 24 个月时计算。
共分析了 19 项随机对照试验,包括 1483 名患者。EVBL 组的总体出血率明显较低:比值比(OR)2.06,95%置信区间(CI)[1.55-2.73],p<0.0001,无发表偏倚证据。18 个月时出血率也明显较低(OR 2.20,95%CI [1.04-4.60],P=0.04),但存在发表偏倚。当仅考虑高质量试验时,出血率的结果不再显著。在总体或 6、12、18 或 24 个月时,均未发现出血相关死亡率或全因死亡率有显著差异。BB 与更频繁的严重不良事件相关(OR 2.61,95%CI 1.60-4.40,P<0.0001),而 EVBL 更频繁发生致命不良事件(OR 0.14,95%CI 0.02-0.99,P=0.05)。
EVBL 似乎优于 BB 预防首次静脉曲张出血,尽管这一发现可能存在偏倚,因为它未被高质量试验证实。死亡率无差异。目前的证据不足以推荐 EVBL 作为一线治疗优于 BB。